# Post-Authorisation Safety Study of Lesinurad

> **NCT04072471** · — · WITHDRAWN · sponsor: **AstraZeneca**

## Conditions studied

- Gout
- Hyperuricemia

## Interventions

- **DRUG:** Zurampic®
- **DRUG:** Control group: xanthine oxidase inhibitor monotherapy

## Key facts

- **NCT ID:** NCT04072471
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-01-29
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was withdrawn as lesinurad was withdrawn from the market in Europe by the market authorization holder. Hence the commitment to do this PASS was removed by the European Medicines Agency.
- **Last updated:** 2021-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04072471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04072471, "Post-Authorisation Safety Study of Lesinurad". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04072471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*